---
input_text: 'Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed
  and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
  BACKGROUND: The treatment of relapsed and/or refractory (R/R) acute myeloid leukemia
  (AML) remains challenging because of poor responses to chemotherapy. Efforts to
  improve outcomes have included the use of high-dose cytarabine in combination with
  nucleoside analogs, such as cladribine. The authors evaluated combined cladribine,
  idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 patients with R/R AML.
  METHODS: Patients received induction with cladribine 5 mg/m2 intravenously (days
  1-5), cytarabine 1000 mg/m2 intravenously (days 1-5), and idarubicin 10 mg/m2 intravenously
  (days 1-3; CLIA). Sorafenib 400 mg twice daily (days 1-14) was added for FLT3-mutated
  AML. RESULTS: The composite response rate (complete remission [CR] plus complete
  remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) patients
  (n = 35) had a CR/CRi rate of 49%. After a 61-month median follow-up, the median
  overall survival (OS) was 7.9 months, with a median relapse-free survival (RFS)
  of 9.1 months for those in CR/CRi. The median OS for S1 patients was 12 months,
  with a median RFS of 10.3 months. For those who received CLIA with sorafenib (n
  = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and median RFS was 3.8
  months. Landmark analysis demonstrated superior OS for patients who proceeded to
  transplantation compared with patients who did not (median OS, 78 vs. 8.8 months,
  respectively; p < .001). The 4-week and 8-week mortality rates were 6% and 17%,
  respectively. Most grade >3 adverse events were related to infection and elevated
  liver function tests. CONCLUSIONS: CLIA is effective for patients with R/R AML and
  offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov
  identifier NCT02115295).'
raw_completion_output: |-
  primary_disease: acute myeloid leukemia
  medical_actions: induction with cladribine; induction with cytarabine; induction with idarubicin; addition of sorafenib for FLT3-mutated AML; transplantation
  symptoms: poor responses to chemotherapy; elevated liver function tests; infection
  chemicals: cladribine; idarubicin; cytarabine; sorafenib
  action_annotation_relationships: induction with cladribine (days 1-5) TREATS poor responses to chemotherapy IN acute myeloid leukemia; induction with cytarabine (days 1-5) TREATS poor responses to chemotherapy IN acute myeloid leukemia; induction with idarubicin (days 1-3) TREATS poor responses to chemotherapy IN acute myeloid leukemia; addition of sorafenib for FLT3-mutated AML TREATS poor responses to chemotherapy IN acute myeloid leukemia; transplantation TREATS poor responses to chemotherapy IN acute myeloid leukemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  transplantation TREATS poor responses to chemotherapy IN acute myeloid leukemia

  ===

extracted_object:
  primary_disease: MONDO:0018874
  medical_actions:
    - induction with cladribine
    - induction with cytarabine
    - induction with idarubicin
    - addition of sorafenib for FLT3-mutated AML
    - MAXO:0000068
  symptoms:
    - poor responses to chemotherapy
    - HP:0002910
    - infection
  chemicals:
    - CHEBI:567361
    - CHEBI:42068
    - CHEBI:28680
    - CHEBI:50924
  action_annotation_relationships:
    - subject: induction
      predicate: TREATS
      object: poor responses to chemotherapy
      qualifier: MONDO:0018874
      subject_qualifier: days 1-5
      subject_extension: CHEBI:567361
    - subject: induction
      predicate: TREATS
      object: poor responses to chemotherapy
      qualifier: MONDO:0018874
      subject_extension: CHEBI:28680
    - subject: induction
      predicate: TREATS
      object: poor responses to chemotherapy
      qualifier: MONDO:0018874
      subject_extension: CHEBI:42068
    - subject: addition of sorafenib
      predicate: TREATS
      object: poor responses to chemotherapy
      qualifier: MONDO:0018874
      subject_qualifier: FLT3-mutated
      subject_extension: CHEBI:50924
    - subject: <transplantation>
      predicate: <TREATS>
      object: <poor responses to chemotherapy>
      qualifier: <acute myeloid leukemia>
      subject_qualifier: <Not applicable>
      object_qualifier: <Not applicable>
      subject_extension: <Not applicable>
      object_extension: <Not applicable>
named_entities:
  - id: MONDO:0018874
    label: Acute myeloid leukemia (AML)
  - id: HP:0001945
    label: Fever
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0020512
    label: T cell acute lymphoblastic leukemia (T-ALL)
  - id: HP:0006727
    label: T-ALL
  - id: CHEBI:50131
    label: Decitabine
  - id: CHEBI:133021
    label: Venetoclax
  - id: HP:0004808
    label: Acute myeloid leukemia
  - id: HP:0002090
    label: pneumonia
  - id: HP:0100806
    label: sepsis
  - id: CHEBI:71019
    label: Homoharringtonine
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:190514
    label: dasatinib
  - id: CHEBI:23456
    label: cyclodextrins
  - id: MAXO:0000747
    label: Hematopoietic Stem Cell Transplantation (HSCT)
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0002018
    label: Nausea
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0100785
    label: Insomnia
  - id: HP:0012531
    label: Pain
  - id: HP:0002019
    label: Constipation
  - id: CHEBI:2038
    label: Azacitidine
  - id: CHEBI:197440
    label: Tumor necrosis factor-alpha (TNF-alpha)
  - id: MONDO:0004967
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0000001
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: HP:0001297
    label: Stroke
  - id: HP:0001635
    label: Heart failure
  - id: HP:0001677
    label: Coronary atherosclerosis
  - id: MONDO:0004992
    label: Cancer
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: MONDO:0004947
    label: B-cell acute lymphoblastic leukemia
  - id: MAXO:0000757
    label: infusion
  - id: MAXO:0000602
    label: Hemodialysis
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002039
    label: Anorexia
  - id: HP:0100519
    label: Anuria
  - id: HP:0011037
    label: Decreased urine output
  - id: HP:0001919
    label: Acute kidney injury
  - id: CHEBI:18332
    label: Levothyroxine
  - id: MONDO:0020511
    label: Acute B-lymphoblastic leukemia (B-ALL)
  - id: HP:0003419
    label: lower back pain
  - id: MONDO:0010651
    label: high-risk myelodysplastic neoplasm (MDS)
  - id: CHEBI:30621
    label: arsenic trioxide
  - id: HP:0002360
    label: sleep disturbances
  - id: MONDO:0017361
    label: Cytokine release syndrome (CRS)
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0012883
    label: Acute promyelocytic leukemia (APL)
  - id: MAXO:0000149
    label: Allogeneic hematopoietic cell transplantation (HCT)
  - id: MONDO:0004948
    label: chronic lymphocytic leukemia
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:63791
    label: lenalidomide
  - id: HP:0005550
    label: chronic lymphocytic leukemia
  - id: MONDO:0003864
    label: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
  - id: MAXO:0001298
    label: therapies
  - id: CHEBI:42068
    label: Idarubicin
  - id: HP:0032169
    label: severe infections
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:85010
    label: eltrombopag
  - id: CHEBI:85012
    label: thrombopoietin receptor agonist (TPO-RA)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001525
    label: intravenous administration
  - id: HP:0002315
    label: Headache
  - id: CHEBI:50858
    label: Corticosteroids
  - id: HP:0100614
    label: myositis
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:76612
    label: Ibrutinib
  - id: CHEBI:167707
    label: Acalabrutinib
  - id: CHEBI:145428
    label: glasdegib
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0010030
    label: bone marrow transplantation
  - id: HP:0001903
    label: anemia
  - id: HP:0001875
    label: neutropenia
  - id: HP:0001698
    label: pericardial effusion
  - id: CHEBI:35705
    label: immunosuppressants
  - id: MONDO:0019460
    label: Acute leukemia of ambiguous lineage (ALAL)
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:62434
    label: FLT3 inhibitor
  - id: CHEBI:38637
    label: Tyrosine kinase inhibitor
  - id: CHEBI:28748
    label: Doxorubicin (Dox)
  - id: HP:0020174
    label: drug resistance
  - id: CHEBI:23888
    label: drugs
  - id: MONDO:0018689
    label: Plasma cell leukemia
  - id: HP:0031047
    label: monoclonal gammopathy
  - id: CHEBI:52726
    label: proteasome inhibitor
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:48120
    label: anthracyclines
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: HP:0001909
    label: leukemia
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: HP:0005506
    label: chronic myeloid leukemia
  - id: MONDO:0005059
    label: Leukemia
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:50729
    label: Mitoxantrone
  - id: CHEBI:50924
    label: Sorafenib
  - id: CHEBI:145372
    label: Gilteritinib
  - id: CHEBI:90217
    label: Quizartinib
  - id: CHEBI:145410
    label: IDH inhibitors
  - id: CHEBI:233585
    label: BAM15
  - id: CHEBI:197439
    label: TNFalpha
  - id: CHEBI:45716
    label: SAHA (Vorinostat)
  - id: HP:0002202
    label: Pleural effusion
  - id: HP:0030357
    label: small cell lung cancer
  - id: HP:0012570
    label: synovial sarcoma
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: MAXO:0000753
    label: Bone marrow examination
  - id: MONDO:0600008
    label: Cytokine release syndrome
  - id: MONDO:0020311
    label: chronic myelomonocytic leukemia
  - id: HP:0012325
    label: chronic myelomonocytic leukemia
  - id: HP:0002488
    label: Acute leukemia
  - id: HP:0003201
    label: Rhabdomyolysis
  - id: HP:0033677
    label: Acute respiratory distress syndrome (ARDS)
  - id: MONDO:0000922
    label: <Primary immunodeficiency disorders (PIDs)>
  - id: MAXO:0000068
    label: transplantation
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:567361
    label: cladribine
